Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
He says the industry will partner with payers to deliver outcomes-driven, sustainable healthcare, in pharmaphorum’s magazine Deep Dive: Market Access.
Delivering better patient benefit and economic returns.
The top 10 pharma milestones of the year to date.
Roche’s MS drug is among major drugs still to come in 2016.
Will NICE introduce fees for pharma companies’ TAs from next year?
Predictive sales analytics can help pharma reps make limited time with healthcare professionals count.
Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
New UK oncology drug assessment procedures examined.